LENSAR, Inc. (LNSR) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. BA
4. HOOD
5. CDNS
6. ANT
7. SPY
8. STX
9. META
10. UPS

Go back to LENSAR, Inc. (LNSR) Tops Q2 EPS by 5c

LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update

August 8, 2022 7:00 AM EDT

Company Receives FDA Clearance of ALLY Adaptive Cataract Treatment System

Second Quarter Procedure Volume Increases 8%, in the Aggregate, and 15% in the U.S. Over Q2 2021 Levels

ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives.

In June, we achieved a significant milestone in LENSARs history, the Food and Drug... More